Literature DB >> 19629686

Prediction of which patients with an abnormal intraoperative cholangiogram will have a confirmed stone at ERCP.

Matthew P Spinn1, David S Wolf, Dharmendra Verma, Frank J Lukens.   

Abstract

BACKGROUND: Abnormal intraoperative cholangiogram (IOC) findings are commonly evaluated using postoperative endoscopic retrograde cholangiopancreatography (ERCP). However, abnormal IOC studies are associated with high false-positive rates. This study aimed to identify a subset of patients with abnormal IOC who would benefit from a postoperative ERCP.
METHODS: This retrospective study investigated 68 patients with abnormal IOC at laparoscopic cholecystectomy (LC) who underwent postoperative ERCP at two tertiary referral centers over a 4-year period. Univariate and multivariate logistic regression analyses were performed to determine predictors of common bile duct (CBD) stones at postoperative ERCP. These predictors included: indication for LC, abnormal liver function tests, white blood cell count (WBC), amylase and lipase, abdominal ultrasound findings, and IOC findings [(1) non-passage of contrast into the duodenum, (2) single stone, (3) multiple stones, (4) dilated CBD, (5) non-visualization of the distal CBD, and (6) palpable CBD stones].
RESULTS: For all 68 patients, ERCP was successful. ERCP showed CBD stones in 36 cases (52.9%), and normal results in 32 cases (47%). On univariate and multivariate analysis, none of the variables included in this study significantly predicted stones at postoperative ERCP.
CONCLUSIONS: Approximately one-half of patients with an abnormal IOC have a normal postoperative ERCP. None of the parameters evaluated in this retrospective study helped identify patients who merit further evaluation by ERCP. The argument could be made that in patients with an abnormal IOC, less invasive methods such as endoscopic ultrasound or magnetic resonance cholangiopancreatography could be used postoperatively if symptoms arise to assess for possible retained stone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629686     DOI: 10.1007/s10620-009-0894-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  45 in total

1.  Evaluation of the predictors of choledocholithiasis: comparative analysis of clinical, biochemical, radiological, radionuclear, and intraoperative parameters.

Authors:  S M Bose; A Mazumdar; V S Prakash; R Kocher; S Katariya; C M Pathak
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

2.  Detection of choledocholithiasis with MR cholangiography: comparison of three-dimensional fast spin-echo and single- and multisection half-Fourier rapid acquisition with relaxation enhancement sequences.

Authors:  J A Soto; M A Barish; O Alvarez; S Medina
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

3.  Cost-effective management of common bile duct stones: a decision analysis of the use of endoscopic retrograde cholangiopancreatography (ERCP), intraoperative cholangiography, and laparoscopic bile duct exploration.

Authors:  D R Urbach; Y S Khajanchee; B A Jobe; B A Standage; P D Hansen; L L Swanstrom
Journal:  Surg Endosc       Date:  2001-01       Impact factor: 4.584

4.  Five-year prospective audit of routine intravenous cholangiography and selective endoscopic retrograde cholangiography with or without intraoperative cholangiography in patients undergoing laparoscopic cholecystectomy.

Authors:  N Pietra; L Sarli; P U Maccarini; G Sabadini; R Costi; S Gobbi
Journal:  World J Surg       Date:  2000-03       Impact factor: 3.352

5.  Do all patients with abnormal intraoperative cholangiogram merit endoscopic retrograde cholangiopancreatography?

Authors:  S Varadarajulu; M A Eloubeidi; C M Wilcox; R H Hawes; P B Cotton
Journal:  Surg Endosc       Date:  2006-03-16       Impact factor: 4.584

6.  Prediction of common bile duct stones by noninvasive tests.

Authors:  F Prat; B Meduri; B Ducot; R Chiche; R Salimbeni-Bartolini; G Pelletier
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

7.  Half-Fourier RARE MR cholangiopancreatography: experience in 300 subjects.

Authors:  A S Fulcher; M A Turner; G W Capps; A M Zfass; K M Baker
Journal:  Radiology       Date:  1998-04       Impact factor: 11.105

8.  Routine cholangiography is not warranted during laparoscopic cholecystectomy.

Authors:  D G Clair; D L Carr-Locke; J M Becker; D C Brooks
Journal:  Arch Surg       Date:  1993-05

9.  Intraoperative cholangiography. A review of indications and analysis of age-sex groups.

Authors:  S B Levine; H J Lerner; E D Leifer; S R Lindheim
Journal:  Ann Surg       Date:  1983-12       Impact factor: 12.969

10.  Preoperative evaluation of the risk of common bile duct stones.

Authors:  F Lacaine; M B Corlette; H Bismuth
Journal:  Arch Surg       Date:  1980-09
View more
  4 in total

1.  Routine ultrasound and blood tests after laparoscopic cholecystectomy-are they worthwhile? A diagnostic accuracy study.

Authors:  Julius Pochhammer; Gunnar Blumenstock; Michael Schäffer
Journal:  Langenbecks Arch Surg       Date:  2016-03-29       Impact factor: 3.445

2.  Evaluation of patients with abnormalities on intraoperative cholangiogram: time to abandon endoscopic retrograde cholangiopancreatography as the initial follow-up study.

Authors:  Jason G Bill; Vladimir M Kushnir; Daniel K Mullady; Faris M Murad; Riad R Azar; Jeffery J Easler; Dayna S Early; Steven A Edmundowicz
Journal:  Frontline Gastroenterol       Date:  2015-06-16

3.  Major biliary complications in 2,714 cases of laparoscopic cholecystectomy without intraoperative cholangiography: a multicenter retrospective study.

Authors:  Mostafa A Hamad; Ahmad A Nada; Mohamad Y Abdel-Atty; Ahmad S Kawashti
Journal:  Surg Endosc       Date:  2011-06-08       Impact factor: 4.584

4.  Identifying patients most likely to have a common bile duct stone after a positive intraoperative cholangiogram.

Authors:  Raja Vadlamudi; Jason Conway; Girish Mishra; John Baillie; John Gilliam; Adolfo Fernandez; John Evans
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.